A Bayesian Approach to the Design of Phase II Clinical Trials

DOI10.2307/2531594zbMATH Open0715.62243OpenAlexW2329151889WikidataQ52553011 ScholiaQ52553011MaRDI QIDQ3201545FDOQ3201545

Authors: R. Sylvester 

Publication date: 1988

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2531594

Recommendations

• Approximately optimal designs for phase II clinical studies
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• A Bayesian decision approach for sample size determination in phase II trials
• Bayesian Optimal Design for Phase II Screening Trials
• Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies

zbMATH Keywords

hypothesis testdecision theoryrisk functionsample sizesmedicinedrug screeningdesign of Phase II clinical trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Cited In (45)

• Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
• Bayesian design for clinical trials with a constraint on the total available dose
• Randomized phase III oncology trials: a survey and empirical Bayes inference
• Adaptive data collection for intraindividual studies affected by adherence
• Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design
• Bayesian designs with frequentist and Bayesian error rate considerations
• Title not available (Why is that?)
• On an approach to Bayesian sample sizing in clinical trials
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
• Bayesian Approaches to Randomized Trials
• Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
• Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
• Bayesian statistics and the efficiency and ethics of clinical trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Approximately optimal designs for phase II clinical studies
• Design and Analysis of Phase II Cancer Trials: A Review of Statistical Methods and Guidelines for Medical Researchers
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome
• Determination of the optimal sample size for a clinical trial accounting for the population size
• Approaches for Optimal Sequential Decision Analysis in Clinical Trials
• Bayesian designs for phase I--II clinical trials
• Bayesian design of clinical trials using joint cure rate models for longitudinal and time-to-event data
• Bayesian Design and Analysis of Active Control Clinical Trials
• Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
• A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
• Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
• Motivating sample sizes in adaptive phase I trials via Bayesian posterior credible intervals
• Optimal Bayesian two-phase designs
• Title not available (Why is that?)
• Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• Bayesian randomized clinical trials: A decision-theoretic sequential design
• Sample sizes of clinical trials: for science and decision making
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Bayesian Optimal Design for Phase II Screening Trials
• Use of bayesian analysis to design of clinical trials with one treatment
• A Bayesian decision approach for sample size determination in phase II trials
• Title not available (Why is that?)
• A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups
• Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach
• Bayesian enrichment strategies for randomized discontinuation trials
• Bayes rules for a clinical-trials model with dichotomous responses
• Bayesian approach to determine the number of subsequent users of a new treatment
• Bayesian doubly adaptive randomization in clinical trials

This page was built for publication: A Bayesian Approach to the Design of Phase II Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201545)